# Tibotec Pharmaceuticals, Ireland clinical trials: 77 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 77 trials with Tibotec Pharmaceuticals, Ireland as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tibotec Pharmaceuticals, Ireland: 77 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/tibotec-pharmaceuticals-ireland

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 77
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 77, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 10, 2014 | NCT02187107 | A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114... | Tibotec Pharmaceuticals, Ireland | Phase 2 | Completed | HIV | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02187107) |
| July 3, 2013 | NCT01891851 | A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01891851) |
| December 6, 2011 | NCT01486004 | A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01486004) |
| November 28, 2011 | NCT01479881 | A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01479881) |
| June 27, 2011 | NCT01381835 | TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01381835) |
| April 18, 2011 | NCT01336829 | TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir. | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C, HIV | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01336829) |
| March 25, 2011 | NCT01323257 | TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01323257) |
| March 4, 2011 | NCT01308658 | TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Healthy | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01308658) |
| March 4, 2011 | NCT01308606 | TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01308606) |
| February 2, 2011 | NCT01288755 | TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | HIV Infections | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01288755) |
| February 2, 2011 | NCT01288742 | TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01288742) |
| February 2, 2011 | NCT01288677 | TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Healthy Volunteer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01288677) |
| January 4, 2011 | NCT01269294 | TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01269294) |
| November 16, 2010 | NCT01241773 | TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01241773) |
| October 19, 2010 | NCT01224197 | TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01224197) |
| September 20, 2010 | NCT01205139 | TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01205139) |
| September 16, 2010 | NCT01202825 | TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01202825) |
| June 2, 2010 | NCT01134718 | TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01134718) |
| May 17, 2010 | NCT01124799 | TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01124799) |
| March 22, 2010 | NCT01090700 | TMC435-TiDP16-C112 - Interaction Trial With Antidepressants | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01090700) |
| March 22, 2010 | NCT01090648 | TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | HIV-Infections | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01090648) |
| January 20, 2010 | NCT01052883 | TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | HIV Infections | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01052883) |
| January 11, 2010 | NCT01046058 | TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435 | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01046058) |
| December 14, 2009 | NCT01031589 | TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | HIV Infections | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01031589) |
| December 1, 2009 | NCT01022125 | TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of... | Tibotec Pharmaceuticals, Ireland | Phase 1 | Completed | Hepatitis C Virus | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01022125) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 45 |
| Phase 2 | 21 |
| Phase 3 | 9 |
| Not applicable | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 72 |
| Approved for marketing | 2 |
| Terminated | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C | 28 |
| HIV Infections | 26 |
| Acquired Immunodeficiency Syndrome | 16 |
| Mycoses | 1 |
| Photosensitivity Disorders | 1 |
| Dermatitis, Phototoxic | 1 |
| Hepatitis C, Chronic | 1 |
| Tuberculosis | 1 |
| Virus Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Logging contractors in the United States](https://specstream.ai/data/businesses/logging-contractors/united-states)
- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
